CAR-T for Myeloma in India: Where BCMA Therapy Stands

Not as an approved treatment. As of August 2026, no BCMA-directed CAR-T product holds CDSCO marketing approval in India. India’s two approved CAR-T products, NexCAR19 and Qartemi, both target CD19 and are not approved for myeloma. BCMA CAR-T reaches Indian patients only inside a clinical trial, or abroad.

The distinction matters more than almost anything else on this page, and it is the one most often lost. Multiple myeloma is a cancer of plasma cells. Myeloma plasma cells carry B-cell maturation antigen, shortened to BCMA. The lymphomas and leukaemias that Indian CAR-T was built for carry CD19 instead.

So a CD19-directed product has nothing to bind to in myeloma. When India approved NexCAR19 in October 2023 and Qartemi in January 2025, the picture changed for lymphoma and leukaemia families. It did not change for myeloma families. Headlines about India’s own CAR-T are accurate and are not about this disease.

Two BCMA CAR-T products are approved elsewhere. Idecabtagene vicleucel, sold as Abecma, and ciltacabtagene autoleucel, sold as Carvykti, are approved by the United States Food and Drug Administration and by the European Medicines Agency for relapsed or refractory myeloma, and the FDA allowed both to move to earlier lines of treatment in April 2024. Neither is registered for marketing in India.

Regulatory statements follow published CDSCO information and the US FDA and European Medicines Agency approvals for the two international products, read in August 2026. Approval status changes. Confirm the current position with a treating haematologist at a licensed cell therapy centre rather than assuming it from this page. Related reading: NexCAR19: India’s First CAR-T Therapy Explained and Qartemi, India’s second approved CAR-T.

Four Indian BCMA programmes are in the public record. They run from a phase 1/2 study that has already treated patients to a dual-target programme still preparing its first-in-human trial. Every one of them is investigational. None is an approved treatment, and a trial place is never assured for any individual patient.

This is a genuinely active area, and it is moving faster than the published patient information about it. What follows is what has been reported publicly, with the source and date for each, so a family can ask about a named programme rather than about CAR-T in the abstract.

The most detailed Indian figures published so far come from SWASTH. At the International Myeloma Society meeting in September 2024, the investigators reported on seven patients treated as of 29 May 2024. The median age was 60. The median number of previous treatment lines was five. Every patient was refractory to three drug classes and five of the seven to five classes. Five patients had reached the six-week response assessment, and all five had responded, two of them completely. Cytokine release syndrome occurred in four of the seven and was mild in each case. One patient had a grade 2 neurological event that settled within 48 hours on steroids. Every patient had a severe fall in neutrophils.

Seven patients is a signal, not a result. Early-phase myeloma trials frequently read well and then have to survive larger numbers and longer follow-up. No durability figure exists for any Indian BCMA product, and none is offered here. The honest summary is that Indian BCMA CAR-T looks worth developing and is not yet a treatment anyone can rely on.

How to find out whether a trial is open. Indian studies are registered on the Clinical Trials Registry — India at ctri.nic.in, searchable by condition. The more practical route is to ask the treating haematologist, who will know which cell therapy centres are enrolling and can send records for review. This page is information about trials, not an invitation to one: enrolment depends on the protocol’s criteria, on a manufacturing slot, and on the investigator’s assessment of the individual patient. CION Cancer Clinics does not run, sponsor or enrol patients into CAR-T trials.

Trial details follow the trial registrations and the conference reports named above, read in August 2026. Trials open, close and change sites without notice, and no statement here should be read as evidence that an investigational product works.

BCMA-directed treatment, yes. BCMA CAR-T, no. Teclistamab, a BCMA-directed T-cell engager given as repeated injections rather than as a one-time cell product, holds a CDSCO import and marketing permission dated September 2023. Anti-CD38 antibodies, proteasome inhibitors, immunomodulatory drugs and autologous stem cell transplant remain the backbone of Indian myeloma care.

Families often arrive at this subject having read that BCMA is the myeloma target and concluded that nothing BCMA-directed is available here. That is not right, and the correction is worth making early, because a treatment that can be started in India this month is a different proposition from one that requires a trial slot or a flight.

Outside the BCMA class, the treatments that carry most Indian myeloma patients furthest are not new and not exotic. Anti-CD38 antibodies, of which daratumumab is the one in routine Indian use and now has Indian biosimilar versions, are used in combination from early in the disease. Proteasome inhibitors such as bortezomib and carfilzomib, immunomodulatory drugs such as lenalidomide and pomalidomide, and autologous stem cell transplant at centres across the country remain the framework of care. Radiotherapy and bone-directed treatment handle the skeletal side of the disease.

Where those are running out, a BCMA-directed T-cell engager is the option that most often comes into the conversation before CAR-T does, because it exists here now. How bispecific antibodies work in blood cancers explains the mechanism, which is close to CAR-T in principle and very different in practice: repeated dosing rather than one infusion, off-the-shelf rather than manufactured from the patient’s own cells, and its own pattern of cytokine release and infection risk. Immunotherapy for multiple myeloma sets out where each of these sits in the sequence.

Regulatory statements above are taken from published CDSCO records, including the list of new drugs of recombinant DNA origin approved for import and marketing in India for September to October 2023 and the Subject Expert Committee recommendations for oncology and haematology, together with the published FDA, European Medicines Agency and UK approvals, all read in August 2026. Which treatment applies to an individual patient is a clinical decision, not one this page can make.

BCMA CAR-T is not a treatment for most people with multiple myeloma, and it is not a treatment for anyone in India outside a clinical trial. Every programme described on this page is studying it in relapsed or refractory disease, in patients who have already been through several lines of treatment. Someone newly diagnosed, or responding to a current regimen, is not a candidate, and would not be offered a trial place.

It is also not for any cancer other than myeloma. BCMA is carried by plasma cells. Solid tumours — breast, lung, head and neck, colorectal, cervical and the rest — are not treated with BCMA-directed CAR-T, and neither are the B-cell lymphomas and leukaemias, which are the province of the CD19 products already approved in India.

Within relapsed myeloma, a haematologist weighs far more than the diagnosis. Heart, lung, kidney and liver function, performance status, active infection, disease in the central nervous system, plasma cell leukaemia, previous cell therapy, and above all whether the disease can be held steady during the weeks the cells take to manufacture. A myeloma that is moving quickly may not allow the time. Any one of these can rule out a patient whose disease otherwise fits the protocol. Practical limits count too: several weeks of stay near a licensed centre, a caregiver, and the cost of the admission and its complications even where a trial supplies the cell product.

This page is also not a recommendation to seek BCMA CAR-T, an offer of a trial place, a price list, or a statement that an investigational product works. CION Cancer Clinics does not provide, administer, stock, price or arrange CAR-T or any other cell therapy. Pages like this one exist to orient a family before a referral, not to substitute for one. Whether CAR-T, a BCMA-directed antibody, or a different line of treatment altogether is right for a particular patient is a decision for a treating haematologist or medical oncologist.

Weeks, not a day. T cells are collected by apheresis and sent for manufacturing, which takes several weeks. Bridging treatment holds the disease steady meanwhile. Short lymphodepleting chemotherapy comes next, then the infusion, then admission with close monitoring and intensive care available on site.

The sequence is worth understanding even while the treatment is out of reach in India, because it explains why eligibility is decided so early and why timing matters as much as the product does.

1. Assessment and eligibility. Disease history, previous lines, organ function, performance status and infection screening. For a trial, the protocol’s own criteria are applied on top. Most patients who reach this stage are told no, and that is a real answer, not a formality.
2. Apheresis. T cells are collected from the blood over a few hours through a machine that returns the rest. What apheresis for CAR-T involves describes the day itself.
3. Manufacturing. The cells are engineered and grown, typically over several weeks. This is the step nothing can hurry, and it is where a fast-moving myeloma can overtake the plan.
4. Bridging treatment. Something has to hold the disease during those weeks. Bridging therapy before CAR-T explains what is used and why.
5. Lymphodepletion and infusion. A short course of chemotherapy makes room for the new cells, then the infusion itself takes very little time.
6. Monitoring. Admission for the early days, then several weeks near the centre. The reactions that matter appear in that window.

The two early risks are the same ones that shape every CAR-T programme. Cytokine release syndrome is an inflammatory reaction, most often in the first days, and can range from fever to circulatory collapse needing intensive care. Immune effector cell-associated neurotoxicity syndrome, or ICANS, is a neurological reaction, usually a little later, treated with steroids. Cytokine release syndrome after CAR-T and ICANS explained cover both.

Later problems are as important and are discussed less. Blood counts can stay low for months. Antibody levels fall, infection risk stays raised, and immunoglobulin replacement is often needed. Delayed neurological effects have been described specifically with BCMA-directed CAR-T, because BCMA is present on some cells outside the bone marrow. Guidance from bodies such as NCCN, ASCO and ESMO treats long-term monitoring after cell therapy as part of the treatment, not an afterthought.

No Indian price exists, because no Indian product is on sale. Inside a trial the cell product is normally supplied by the sponsor, while work-up, admission and complication care are still billed. Abroad, BCMA CAR-T runs into hundreds of thousands of US dollars. All figures here are indicative, as of August 2026.

Two reference points give a family a sense of scale without pretending to be a quotation. India’s CD19 products have been described in Indian reporting from October 2023 onwards in a band of roughly ₹30–40 lakh for the product alone, indicative as of August 2026. Abroad, in a July 2025 patient-education interview, Dr Hari Menon, Professor of Haematology at St John’s National Academy of Health Sciences, Bengaluru, put Western CAR-T at about US$250,000 for the product and US$400,000 to US$500,000 once supportive care is counted.

Neither figure is a price for BCMA CAR-T in India, and nobody can give one, because there is nothing approved to price. What the numbers do explain is why the Indian programmes describe themselves as cost-efficient, and why the domestic pipeline matters to families here far more than any international approval does. CION Cancer Clinics does not price, quote, supply or arrange any CAR-T product.

What is genuinely unknown deserves saying plainly, because this field attracts more certainty than it has earned. How long responses to BCMA CAR-T last in Indian patients is unknown, because the follow-up does not yet exist. What works best after a BCMA product stops working is an open question worldwide. Whether dual-target BCMA and CD19 designs hold responses longer than single-target ones is exactly what the Indian trials are asking, and the answer is not in. Long-term safety after cell therapy, including second cancers, is still accumulating everywhere. Anyone presenting any of this as settled is going past the evidence.

On the money side, what applies to CD19 CAR-T today is the closest available guide. NexCAR19 Cost and How Families Pay for It sets out the funding routes Indian families actually use, what CAR-T costs in India breaks down the parts of the bill beyond the product, and insurance and scheme coverage for CAR-T covers what policies have paid for so far.

Every figure above is drawn from a named published source and dated, is indicative only as of August 2026, and is not a cost estimate for any individual patient. Only a treating centre can issue a written estimate.

The pages below cover the CAR-T that India does have, what it costs, who it is for, and how a referral to a licensed cell therapy centre works.

• NexCAR19: India’s First CAR-T Therapy Explained — the CD19 product that changed the picture for lymphoma and leukaemia, and why it does not apply to myeloma.
• NexCAR19 Cost and How Families Pay for It — the published price figures, what they exclude, and the funding routes families use.
• Who Is Eligible for NexCAR19? — how a cell therapy centre assesses a patient, which is the same assessment a myeloma trial applies.
• The CAR-T referral pathway in India — how a patient actually reaches a licensed centre, and what to carry to the first appointment.
• Where CAR-T therapy is available in India — what makes a centre licensed for cell therapy and how to check one.
• Immunotherapy for multiple myeloma — where BCMA-directed treatment sits alongside the rest of myeloma care.
• Immunotherapy Medicines Explained — the index of checkpoint inhibitors, biosimilars, cell therapies and molecule comparisons.
• Immunotherapy at a glance — what this family of treatments does, who it is for, and who it is not for.

Editorial and referral orientation on the position of BCMA-directed CAR-T for multiple myeloma in India — not an offer, a price list, an invitation to a clinical trial, or a recommendation to use any product named here. CION Cancer Clinics does not provide, administer, stock, price or arrange CAR-T or any other cell therapy. All approval, trial and cost statements are indicative and dated to August 2026, drawn from published regulatory records, trial registrations, conference reports and named published sources, and can change. Whether any treatment on this page applies to you is a decision for your treating haematologist or medical oncologist.